ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On February 9, 2017, Jennifer Cheng, Ph.D, J.D., age 44, was appointed to serve as the vice president and general counsel of Adverum Biotechnologies, Inc. (the “Company”). Dr. Cheng has served as vice president and associate general counsel of the Company since February 2016, and previously served as the senior patent counsel, director of intellectual property of the Company from June 2015 to February 2016. Prior to joining the Company, she served as a patent counsel at Allergan plc, a global pharmaceutical company, from March 2013 to May 2015 and as the senior patent counsel at MAP Pharmaceuticals, a biotechnology company, from June 2011 until its acquisition by Allergan in March 2013. From August 2008 to May 2011, Dr. Cheng served as the manager of intellectual property at Solazyme, Inc., a biotechnology company, and previously was a patent counsel at Raven Biotechnologies, Inc., a biotechnology company. Dr. Cheng received a B.A. from the University of California, Berkeley, a Ph.D. in tumor cell biology and molecular medicine from Northwestern University and a J.D. from Santa Clara University School of Law.

There are no family relationships between Dr. Cheng and any director or executive officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer. There are no arrangements or understandings between Dr. Cheng and any other persons to which she was selected as vice president and general counsel. Dr. Cheng has no direct or indirect material interest in any transaction or currently proposed transaction required to be disclosed to Item 404(a) of Regulation S-K.

About ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Recent Trading Information

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) closed its last trading session down -0.10 at 2.90 with 495,402 shares trading hands.